Neurogastrx To Present Novel Gastroparesis Drug Candidate In Podium Presentation At Digestive Disease Week 2016
23 May 2016
Collaborate
Lecture to highlight potent dopamine receptor antagonist with limited propensity
to cross blood brain barrier
Campbell, CA – May 23, 2016 – Neurogastrx, a biopharmaceutical company engaged in
developing novel drugs for gastrointestinal disorders, today announced the Company will
present data from its lead gastrointestinal research program during Digestive Disease Week
(DDW) 2016 in San Diego, May 21 through May 24, 2016. Cyril De Colle, Ph.D., Neurogastrx’
Chief Scientific Officer will deliver the oral presentation detailing data from nonclinical studies of
the Company’s lead drug candidate, NG101, a potent and selective dopamine receptor
antagonist, the only class of drugs approved for gastroparesis.
The abstract to be presented follows and may be viewed in full here.
Tuesday, May 24, 2:00-3:30pm:
AGA Session: Gastroparesis: Bench to Bedside
Oral Session #1079: “NG101: A Potent and Selective Dopamine D2 Receptor Antagonist as a
Potential Alternative to Metoclopramide and Domperidone for the Treatment of Gastroparesis”
“Existing dopamine receptor antagonists and various formulations of these agents are not
satisfactory therapeutic interventions due to neurological or cardiovascular side effects.
Neurological side effects occur primarily due to these agents crossing the blood brain barrier
(BBB) and interfering with dopamine receptors in the central nervous system. Our data show
NG101 does not readily cross the BBB; therefore, we believe NG101 will prove to be a safer
alternative to these agents and offer physicians a welcome therapeutic alternative for the
treatment of gastroparesis”, stated Dr. De Colle.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.